NCT07597421Not yet recruiting
Fecal Microbiota Transplantation in Parkinson's Disease.
Fecal Microbiota Transplantation for the Treatment of Patients With Parkinson's Disease.
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
Fecal microbiota transplantation (FMT) is an effective and safe treatment for Clostridioides difficile infection (CDI). Though CDI is the only indication for FMT, more and more preliminary data on FMT in neurological disorders are reported due to gut-brain axis. This study is a pilot study to apply FMT on patients with Parkinson's disease (PD). The effect of FMT on motor and non-motor symptoms in PD will be also evaluated.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- First submitted
- 13 May 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 7 Apr 2029
- Lead sponsor
- Chang Gung Memorial Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT07597421
What you commit to
- Study type: Interventional
- Planned participants: 58
- From 1 Sept 2026 to the primary completion date, 7 Apr 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current need of antibiotics or use in the previous 3 months.
Other illness
- Dementia (MMSE\<24), history of encephalitis, or brain organic lesions, including congenital or acquired structural abnormalities (which were detected through brain computed tomography scan or Magnetic Resonance Imaging) may affect neurological function, leading to various neurological deficits and mpairing the cognitive function.
- End stage renal disease caused uremic encephalopathy or liver cirrhosis caused hepatic encephalopathy
Other
- Hoehn-Yahr stage 5. (wheelchair ridden or bedridden due to PD)
- Current use of probiotics or in the past 3 months.
- For women with childbearing potential. (Female participants are suggested to prevent pregnancy during this trial and undergo a pregnancy test before enrollment.)
- Immunocompromised state.
Who the study is looking for
- Clinical diagnosis of idiopathic PD according to UK brain bank criteria.
- PD disease duration ≧5 years to avoid the possible misdiagnosis of atypical parkinsonism.
- Hoehn-Yahr stage 1-4
- Using levodopa in a currently fixed dose.
- Presence of motor complications (motor fluctuation or dyskinesia).
- Written informed consent.
- Age above 18.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.